Basel, Switzerland (UroToday.com) Dr. Morgans presented the IRONMAN project, which is the international registry for men with advanced prostate cancer.There are an estimated 1.3 million new cases of prostate cancer and 359,000 prostate cancer deaths globally each year. This is a rapidly evolving clinical landscape and there is variability in guidelines and clinical practice in advanced […]
Basel, Switzerland (UroToday.com) Dr. Joe M. O’Sullivan spoke on the aging population and how to properly assess them in the context of prostate cancer. Life expectancy has been consistently rising since 1950 and is expected to continue to rise in 2050 (figure 1). The age at diagnosis of prostate cancer is shown in figure 2 and […]
Basel, Switzerland (UroToday.com) Dr. Fernando Maluf summarized the results of the first consensus conference for developing countries. This unique conference provided guidelines for prostate cancer, specifically for areas of limited resources, comprising 70-75% of the world’s population, shown in (Figure 1) from Dr. Maluf’s Advanced Prostate Cancer Consensus Conference (APCCC) 2019 presentation. The methodology applied in the […]
Basel, Switzerland (UroToday.com) Dr. Alicia Morgans presented on disparities in prostate cancer management in the United States. She began her presentation stating that social health is determined by many factors (Figure 1) which could be responsible for these disparities. There were 174650 new cases of prostate cancer in the US in 2019. Black Americans have […]
Basel, Switzerland (UroToday.com) Dr. Alicia Morgans presented on disparities in prostate cancer management in the United States. She began her presentation stating that social health is determined by many factors (Figure 1) which could be responsible for these disparities. There were 174650 new cases of prostate cancer in the US in 2019. Black Americans have […]
Basel, Switzerland (UroToday.com) Michael Morris, MD, discussed de novo oligometastatic prostate cancer at the APCCC 2019 session on PSA recurrence after radical local therapy and oligometastatic prostate cancer. According to Dr. Morris, de novo oligometastatic disease represents a unique treatment opportunity, such that it is an untreated primary, untreated metastatic disease with limited distribution. Prolonging OS […]
Basel, Switzerland (UroToday.com) Dr. Christopher Logothetis opened the regional care (demographic and environmental factors) session at the Advanced Prostate Cancer Consensus Conference the (APCCC) 2019 meeting. His presentation focused on ethnicity and prognosis of prostate cancer. Prostate cancer is an emergent international challenge. It is interesting to explore whether there are international differences in reported incidences and […]
Basel, Switzerland (UroToday.com) At the APCCC 2019 session on prostate-specific antigen (PSA) recurrence after radical local therapy and oligometastatic prostate cancer, Dr. Eric Small from UCSF discussed treatment of oligometastatic and oligoprogressive CPRC. Oligometastatic CRPC is defined as a limited number of metastases in a patient who has ADT-refractory prostate cancer, whereas oligoprogressive CRPC is defined […]
Basel, Switzerland (UroToday.com) Dr. Alberto Bossi spoke about the recommended treatment of men with pathological node-positive prostate cancer. These patients are becoming more common as surgery is being performed on a higher proportion of high-risk patients with positive nodes. Data presented at AUA 2018 by Bandini et al. from three referral centers in Italy, demonstrated that the […]
Basel, Switzerland (UroToday.com) Dr. Piet Ost from Belgium discussed treatment of oligorecurrent prostate cancer after local therapy at the APCCC 2019 biennial meeting. Dr. Ost notes that this is defined as a patient with a treated (and controlled) primary tumor, is naïve to systemic treatment, and has N1 or M1 metastasis. Currently, there is no consensus […]
